Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

The potential anti-amyloidogenic candidate, SPA1413, for Alzheimer's disease

Authors
An, Seong Soo A.Shim, Kyu HwanKang, ShinwooKim, Young KyoSubedi, LalitaCho, HyewonHong, Seong-MinTan, Mario A.Jeon, RaokChang, Keun-AKim, Sun Yeou
Issue Date
Mar-2022
Publisher
WILEY
Keywords
Alzheimer' s disease; drug discovery; isoflavone; neuroinflammation; oligomerization
Citation
BRITISH JOURNAL OF PHARMACOLOGY, v.179, no.5, pp.1033 - 1048
Journal Title
BRITISH JOURNAL OF PHARMACOLOGY
Volume
179
Number
5
Start Page
1033
End Page
1048
URI
https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/145869
DOI
10.1111/bph.15691
ISSN
0007-1188
Abstract
Background and Purpose Recently, isoflavone derivatives have been shown to have neuroprotective effects against neurological disorders. For instance, genistein attenuated the neuroinflammation and amyloid-beta accumulation in Alzheimer's disease animal models, suggesting the potential for use to prevent and treat Alzheimer's disease. Experimental Approach Here, 50 compounds, including isoflavone derivatives, were constructed and screened for the inhibitory effects on amyloid-beta(42) fibrilization and oligomerization using the high-throughput screening formats of thioflavin T assay and multimer detection system, respectively. The potential neuroprotective effect of t3-(4-hydroxyphenyl)-2H-chromen-7-ol (SPA1413), also known as dehydroequol, idronoxil or phenoxodiol, was evaluated in cells and in 5xFAD (B6SJL) transgenic mouse, a model of Alzheimer's disease. Key Results SPA1413 had a potent inhibitory action on both amyloid-beta fibrilization and oligomerization. In the cellular assay, SPA1413 prevented amyloid-beta-induced cytotoxicity and reduced neuroinflammation. Remarkably, the oral administration of SPA1413 ameliorated cognitive impairment, decreased amyloid-beta plaques and activated microglia in the brain of 5xFAD (B6SJL) transgenic mouse. Conclusion and Implications Our results strongly support the repurposing of SPA1413, which has already received fast-track status from the US Food and Drug Administration (FDA) for cancer treatment, for the treatment of Alzheimer's disease due to its potent anti-amyloidogenic and anti-neuroinflammatory actions.
Files in This Item
There are no files associated with this item.
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jeon, Ra Ok photo

Jeon, Ra Ok
약학대학 (약학부)
Read more

Altmetrics

Total Views & Downloads

BROWSE